JP2014503528A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503528A5
JP2014503528A5 JP2013543881A JP2013543881A JP2014503528A5 JP 2014503528 A5 JP2014503528 A5 JP 2014503528A5 JP 2013543881 A JP2013543881 A JP 2013543881A JP 2013543881 A JP2013543881 A JP 2013543881A JP 2014503528 A5 JP2014503528 A5 JP 2014503528A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
formula
use according
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013543881A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014503528A (ja
Filing date
Publication date
Priority claimed from GBGB1021161.3A external-priority patent/GB201021161D0/en
Priority claimed from GBGB1109162.6A external-priority patent/GB201109162D0/en
Application filed filed Critical
Priority claimed from PCT/GB2011/052475 external-priority patent/WO2012080729A2/en
Publication of JP2014503528A publication Critical patent/JP2014503528A/ja
Publication of JP2014503528A5 publication Critical patent/JP2014503528A5/ja
Pending legal-status Critical Current

Links

JP2013543881A 2010-12-14 2011-12-14 カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用 Pending JP2014503528A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1021161.3A GB201021161D0 (en) 2010-12-14 2010-12-14 Casein kinase 1delta (CK1Delta) inhibitors
GB1021161.3 2010-12-14
GBGB1109162.6A GB201109162D0 (en) 2011-06-01 2011-06-01 Casein kinase 1Delta (CK1Delta) inhibitors
GB1109162.6 2011-06-01
PCT/GB2011/052475 WO2012080729A2 (en) 2010-12-14 2011-12-14 CASEIN KINASE 1δ (CK1δ) INHIBITORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016175298A Division JP2017025080A (ja) 2010-12-14 2016-09-08 カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用

Publications (2)

Publication Number Publication Date
JP2014503528A JP2014503528A (ja) 2014-02-13
JP2014503528A5 true JP2014503528A5 (enExample) 2014-12-25

Family

ID=45444638

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013543881A Pending JP2014503528A (ja) 2010-12-14 2011-12-14 カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用
JP2013543879A Expired - Fee Related JP5937102B2 (ja) 2010-12-14 2011-12-14 カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
JP2016095027A Active JP6243472B2 (ja) 2010-12-14 2016-05-11 カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
JP2016175298A Withdrawn JP2017025080A (ja) 2010-12-14 2016-09-08 カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013543879A Expired - Fee Related JP5937102B2 (ja) 2010-12-14 2011-12-14 カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
JP2016095027A Active JP6243472B2 (ja) 2010-12-14 2016-05-11 カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
JP2016175298A Withdrawn JP2017025080A (ja) 2010-12-14 2016-09-08 カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用

Country Status (10)

Country Link
US (5) US20140031547A1 (enExample)
EP (3) EP2651405A2 (enExample)
JP (4) JP2014503528A (enExample)
CN (3) CN104906103B (enExample)
AU (2) AU2011343039B2 (enExample)
CA (1) CA2818903C (enExample)
DK (1) DK2835131T3 (enExample)
ES (2) ES2650744T3 (enExample)
HK (1) HK1214527A1 (enExample)
WO (2) WO2012080727A2 (enExample)

Families Citing this family (243)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CA2711558C (en) 2008-01-04 2016-12-13 Intellikine, Inc. Phosphatidyl inositol-3 kinase inhibiting compounds
EP2845856A1 (en) 2009-06-29 2015-03-11 Incyte Corporation Pyrimidinones as PI3K inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2552208A4 (en) * 2010-03-31 2014-07-09 Glaxo Group Ltd IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
EP2558463A1 (en) 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
US20140031547A1 (en) * 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
TW201249844A (en) 2010-12-20 2012-12-16 Incyte Corp N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
AU2012205669B2 (en) 2011-01-10 2015-08-20 Infinity Pharmaceuticals Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
UA121539C2 (uk) 2011-09-02 2020-06-25 Інсайт Холдинґс Корпорейшн Гетероцикліламіни як інгібітори рі3к
CA2851087C (en) 2011-10-07 2019-09-24 Takeda Pharmaceutical Company Limited 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
LT2772484T (lt) 2011-10-18 2017-12-27 Astellas Pharma Inc. Biciklinis heterociklinis junginys
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
JP6141864B2 (ja) 2011-12-01 2017-06-07 ケモセントリックス，インコーポレイティド Ｃｃｒ（４）アンタゴニストとしての置換アニリン
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TWI633087B (zh) 2012-06-13 2018-08-21 赫孚孟拉羅股份公司 新穎二氮雜螺環烷及氮雜螺環烷
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP6299591B2 (ja) * 2012-07-03 2018-03-28 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
WO2014009891A1 (en) * 2012-07-11 2014-01-16 Piramal Enterprises Limited Heterocyclic compounds for use in the treatment of cancers
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
DK2888010T3 (da) 2012-08-22 2021-06-28 Univ Cornell Fremgangsmåder til at hæmme fascin
JP6219955B2 (ja) * 2012-08-24 2017-10-25 トレヴェンティス コーポレイションＴｒｅｖｅｎｔｉｓ Ｃｏｒｐｏｒａｔｉｏｎ ベンゾフラザン抗アミロイド化合物および方法
CN102850341B (zh) * 2012-09-05 2015-02-18 浙江工业大学 一种噻二唑类化合物及其制备与应用
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
EP3590940B1 (en) 2012-09-25 2021-06-09 F. Hoffmann-La Roche AG Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
CN103739594A (zh) * 2012-10-17 2014-04-23 南京大学 一类含吡嗪环和三氮唑结构的席夫碱类衍生物及其制法
KR102229478B1 (ko) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
RU2672916C2 (ru) 2012-11-27 2018-11-21 Томас Хелледайс Стифтелсе Фёр Медисинск Форскнинг Производные пиримидин-2,4-диамина для лечения рака
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US20150329540A1 (en) 2012-12-28 2015-11-19 Shin Nippon Biomedical Laboratories, Ltd. Oct3 activity inhibitor containing imidazopyridine derivative as active component, and oct3 detection agent
NZ710444A (en) 2013-02-11 2020-08-28 Univ California Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
US9045477B2 (en) 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JP2016520532A (ja) 2013-03-15 2016-07-14 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ベンゾイミダゾール誘導体およびその使用
US9776996B2 (en) 2013-03-15 2017-10-03 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
US9797882B2 (en) 2013-07-09 2017-10-24 The Translational Genomics Research Institute Method of screening for a compound for inhibitory activity of FN14-tweak interaction
EP3019874B1 (en) * 2013-07-09 2019-08-21 The Translational Genomics Research Institute Compositions and methods of screening for compounds that modulate activity at a tweak binding site on a crd of fn14
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
RU2570907C2 (ru) * 2013-10-21 2015-12-20 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа.
CA2929858C (en) 2013-11-22 2022-03-29 CL BioSciences LLC Gastrin antagonists (eg yf476, netazepide) for treatment and prevention of osteoporosis
NO3074400T3 (enExample) 2013-11-26 2018-04-14
GB201321738D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
WO2015106025A1 (en) * 2014-01-09 2015-07-16 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Substituted benzoxazine and related compounds
US9815841B2 (en) 2014-01-29 2017-11-14 Glaxosmithkline Intellectual Property Development Limited Compounds
KR20160106622A (ko) 2014-01-29 2016-09-12 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 화합물
CA2939219C (en) 2014-02-11 2023-02-28 Mitokinin Llc Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
KR102421235B1 (ko) 2014-02-13 2022-07-15 인사이트 코포레이션 Lsd1 저해제로서 사이클로프로필아민
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
NZ723203A (en) 2014-02-13 2020-08-28 Incyte Corp Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2015127125A1 (en) 2014-02-20 2015-08-27 Cornell University Compounds and methods for inhibiting fascin
RS58976B1 (sr) * 2014-02-27 2019-08-30 Treventis Corp Antiamiloidna jedinjenja koja sadrže benzofuran
EP3122751B1 (en) 2014-03-26 2019-10-30 F.Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
MA39792B1 (fr) 2014-03-26 2019-12-31 Hoffmann La Roche Composés bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa)
US20170029388A1 (en) * 2014-04-11 2017-02-02 Intercontinental Great Brands Llc Treatment of Neurodegenerative Diseases with Asparagine Endopeptidase (AEP) Inhibitors and Compositions Related Thereto
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
CN105085436B (zh) * 2014-04-19 2019-08-16 广东东阳光药业有限公司 磺酰胺类衍生物及其在药物上的应用
EP3134413B1 (en) 2014-04-23 2019-09-11 Dart NeuroScience (Cayman) Ltd. Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors
EP3140298A1 (en) 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-related kinase inhibitors
CN104059060B (zh) * 2014-05-30 2017-08-01 西安交通大学 一种5‑(1h‑吲哚‑3‑亚甲基)‑1,3‑噻唑烷‑4‑酮类衍生物及其合成方法和应用
CA2949785A1 (en) 2014-06-04 2015-12-10 Thomas Helledays Stiftelse For Medicinsk Forskning Mth1 inhibitors for treatment of cancer
CN106794181A (zh) 2014-06-04 2017-05-31 托马斯·黑勒戴药物研究基金会 用于治疗炎性和自身免疫性病况的mth1抑制剂
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
JP6571756B2 (ja) 2014-07-31 2019-09-04 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 神経変性疾患に適応可能なインドリジン誘導体
JP2017523211A (ja) 2014-08-04 2017-08-17 ドレクセル ユニバーシティ 新規化合物およびそれを用いてｉｌ−１ｒ媒介性の疾患または障害を処置するかまたは寛解させる方法
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
GB201419579D0 (en) * 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
WO2016073424A1 (en) 2014-11-05 2016-05-12 Dart Neuroscience, Llc Substituted 5-methyl-[1, 2, 4] triazolo [1,5-a) pyrimidin-2-amine compounds as pde2 inhibitors
JP6708130B2 (ja) 2014-12-25 2020-06-10 小野薬品工業株式会社 キノリン誘導体
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
SG11201706287PA (en) 2015-02-20 2017-09-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
UA122332C2 (uk) 2015-02-27 2020-10-26 Інсайт Корпорейшн Солі інгібітора pi3k і способи їх отримання
US10722513B2 (en) * 2015-03-23 2020-07-28 The University Of Melbourne Treatment of respiratory diseases
UA122688C2 (uk) 2015-04-03 2020-12-28 Інсайт Корпорейшн Гетероциклічні сполуки як інгібітори lsd1
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
AU2016254049A1 (en) * 2015-04-30 2017-11-02 Musc Foundation For Research Development Oxindole compounds and pharmaceutical compositions thereof
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
GB201508276D0 (en) 2015-05-14 2015-06-24 Electrophoretics Ltd A casein kinase 1 delta inhibitor
GB201509134D0 (en) 2015-05-28 2015-07-15 Electrophoretics Ltd Biomolecules involved in Alzheimer's disease
MX2017015456A (es) * 2015-06-01 2018-11-29 Bantam Pharmaceutical Llc Compuestos de pirazol y pirrol sustituidos y metodos para su uso por inhibición de iniciación de traducción y tratamiento de enfermedades y trastornos relacionados con ellos.
WO2016202756A1 (en) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
WO2016202758A1 (en) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
JP2018525345A (ja) 2015-07-01 2018-09-06 ノースウェスタン ユニバーシティ 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
JP7427363B2 (ja) 2015-08-12 2024-02-05 インサイト・ホールディングス・コーポレイション Ｌｓｄ１阻害剤の塩
CN105061462B (zh) * 2015-08-18 2017-05-24 沈阳药科大学 含有酰胺的四氢苯并[4,5]噻吩并[2,3‑d]嘧啶类化合物及其应用
MX387736B (es) * 2015-09-04 2025-03-18 Hoffmann La Roche Derivados de fenoximetilo.
JP6469238B2 (ja) 2015-09-18 2019-02-13 科研製薬株式会社 ビアリール誘導体及びそれを含有する医薬
KR20180054634A (ko) 2015-09-24 2018-05-24 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 신규한 이환형 화합물
MX2017015034A (es) 2015-09-24 2018-04-13 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
CN107635995B (zh) 2015-09-24 2022-08-19 豪夫迈·罗氏有限公司 作为atx抑制剂的二环化合物
PE20180451A1 (es) 2015-09-24 2018-03-05 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores de atx
US20190112317A1 (en) 2015-10-05 2019-04-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
WO2017063966A1 (en) 2015-10-13 2017-04-20 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-benzothiazole compounds
UA122423C2 (uk) * 2015-11-02 2020-11-10 Янссен Фармацевтика Нв [1,2,4]ТРИАЗОЛО[1,5-a]ПІРИМІДИН-7-ІЛЬНА СПОЛУКА
WO2017097182A1 (zh) * 2015-12-07 2017-06-15 成都海创药业有限公司 喹啉类化合物及其制备方法和作为尿酸盐转运体抑制剂类药物的用途
WO2017106367A1 (en) * 2015-12-15 2017-06-22 D.E. Shaw Research, Llc Method of treating neurodegenerative disorders by rescuing alpha-synuclein toxicity
WO2017133258A1 (zh) * 2016-02-04 2017-08-10 西华大学 1h-吲唑类衍生物及其作为ido抑制剂的用途
CN107033087B (zh) * 2016-02-04 2020-09-04 西华大学 1h-吲唑-4-胺类化合物及其作为ido抑制剂的用途
CN107840826B (zh) * 2016-09-19 2021-07-09 西华大学 1h-吲唑类衍生物及其作为ido抑制剂的用途
US10166221B2 (en) 2016-04-22 2019-01-01 Incyte Corporation Formulations of an LSD1 inhibitor
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
EA202092442A3 (ru) 2016-06-07 2021-08-31 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
MX391135B (es) 2016-06-24 2025-03-21 Infinity Pharmaceuticals Inc Terapias de combinacion.
MX2019000536A (es) 2016-07-14 2019-04-01 Pfizer Nuevas pirimidinas carboxamidas como inhibidores de enzima vanina-1.
WO2018030762A1 (ko) * 2016-08-09 2018-02-15 세종대학교산학협력단 Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물
CA3034211A1 (en) 2016-08-18 2018-02-22 Vidac Pharma Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
EP3872080B1 (en) 2016-09-02 2023-08-16 Cyclerion Therapeutics, Inc. Fused bicyclic sgc stimulators
CN106432235B (zh) * 2016-10-19 2018-02-02 南通大学 靶向CDK和DNA的β‑咔啉衍生物及其制备方法和医药用途
JP2019533022A (ja) 2016-10-24 2019-11-14 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
KR20190071721A (ko) 2016-11-02 2019-06-24 얀센 파마슈티카 엔.브이. Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 화합물
UA125302C2 (uk) * 2016-11-02 2022-02-16 Янссен Фармацевтика Нв Похідні [1,2,4]триазоло[1,5-a]піримідину як інгібітори pde2
MA46690A (fr) * 2016-11-02 2019-09-11 Janssen Pharmaceutica Nv Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
US11008325B2 (en) 2016-11-14 2021-05-18 Virginia Commonwealth University Inhibitors of cancer invasion, attachment, and/or metastasis
US20190358238A1 (en) * 2016-11-16 2019-11-28 University Of South Florida ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
CA3049010A1 (en) 2017-01-06 2018-07-12 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
CN116462666B (zh) * 2017-01-10 2025-07-15 瑞士苏黎世联邦理工学院 细胞保护性化合物及其用途
CN106831573B (zh) * 2017-01-23 2019-05-24 南阳师范学院 (n-1,2,3,4-四氢异喹啉基)-阿魏酰胺化合物、制备方法及其应用
CN106748969B (zh) * 2017-01-23 2019-06-18 南阳师范学院 一种n-(4-苄基哌啶基)-阿魏酰胺化合物、制备方法及其用途
BR112019014814B1 (pt) 2017-01-23 2024-03-12 Novartis Ag Compostos, composições farmacêuticas dos mesmos e seus usos no tratamento de doenças associadas à disfunção de canais iônicos de potássio
ES2872923T3 (es) 2017-01-26 2021-11-03 Ono Pharmaceutical Co Sal etanosulfonato de N-{5-[(6,7-dimetoxi-4-quinolinil)oxi]-2-piridinil}-2,5-dioxo-1-fenil-1,2,5,6,7,8-hexahidro-3-quinolinacarboxamida
NZ755447A (en) * 2017-02-01 2023-05-26 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd N1 -(4-(5-(cyclopropylmethyl)-1 -methyl-1 h-pyrazol-4-yl)pyridin-2-yl)cyclohexane-1,4-diamine derivatives and related compounds as ck1 and/or iraki inhibitors for treating cancer
CN109730996B (zh) * 2017-03-01 2021-08-24 浙江大学 喹啉结构类型雄激素受体拮抗剂及其应用
MA49879A (fr) 2017-03-16 2020-06-24 Hoffmann La Roche Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
EP3680241A1 (en) 2017-03-20 2020-07-15 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
WO2018172984A1 (en) 2017-03-23 2018-09-27 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
MX2021011775A (es) 2017-04-26 2023-01-10 Basilea Pharm Int Ag Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos.
EP3634406B1 (en) * 2017-05-12 2023-09-06 Board of Trustees of The Southern Illinois University on behalf of Southern Illinois University Edwardsville 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
UY37759A (es) 2017-06-09 2019-01-31 Novartis Ag Compuestos y composiciones para inducir condrogénesis
CN110997664A (zh) * 2017-06-14 2020-04-10 欧洲分子生物学实验室 用于疗法的苯并呋喃酰胺及其杂芳族类似物
KR20200019228A (ko) 2017-06-21 2020-02-21 미토키닌, 인크. 신경퇴행성 및 미토콘드리아 질환의 치료를 위한 조성물 및 이를 사용하는 방법
GB201710851D0 (en) * 2017-07-06 2017-08-23 Galápagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
JP7258009B2 (ja) 2017-07-10 2023-04-14 セルジーン コーポレイション 抗増殖化合物及びその使用方法
CA3069720A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
JP7159173B2 (ja) 2017-09-11 2022-10-24 保土谷化学工業株式会社 ピリミジン環構造を有する化合物および有機エレクトロルミネッセンス素子
WO2019055877A1 (en) 2017-09-15 2019-03-21 Forma Therapeutics, Inc. TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
HUE070649T2 (hu) 2017-10-19 2025-06-28 Teijin Pharma Ltd Benzimidazol-származékok és felhasználásuk
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
EP3728200A1 (en) * 2017-12-21 2020-10-28 Gliapharm SA Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
JP2021507945A (ja) * 2017-12-21 2021-02-25 グリアファーム エスエー 認知症を含む神経障害のための組成物および治療方法
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
EP3762383B1 (en) * 2018-03-06 2023-12-06 The United States of America, as represented by the Secretary, Department of Health and Human Services Positive allosteric modulators of dopamine 1 receptor and method of use thereof
EP3543231A1 (en) * 2018-03-19 2019-09-25 ETH Zurich Compounds for treating cns- and neurodegenerative diseases
CA3094527A1 (en) 2018-03-23 2019-09-26 Yumanity Therapeutics, Inc. Compounds and uses thereof
MX2020011718A (es) 2018-05-04 2021-02-15 Incyte Corp Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
ES3061844T3 (en) 2018-05-04 2026-04-07 Incyte Corp Salts of an fgfr inhibitor
TWI815887B (zh) * 2018-05-15 2023-09-21 美商愛彼特生物製藥股份有限公司 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
MX2020012826A (es) 2018-06-01 2021-03-09 Incyte Corp Regimen de dosificacion para el tratamiento de trastornos relacionados con fosfatidilinositol 3-cinasas (pi3k).
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
KR20250067962A (ko) 2018-06-29 2025-05-15 포르마 세라퓨틱스 인크. Creb 결합 단백질(cbp)의 저해
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
MX2021001456A (es) * 2018-08-06 2021-05-27 Univ Leland Stanford Junior 2-arilbenzimidazoles como activadores de ppargc1a para tratar enfermedades neurodegenerativas.
ES3064498T3 (enExample) 2018-08-29 2026-04-27 Chemocentryx Inc
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
US11278527B2 (en) 2018-09-04 2022-03-22 Brown University Compositions and methods for the modulation of the corticotropin releasing factor binding protein and the treatment of alcohol use disorder
MX2021002652A (es) * 2018-09-09 2021-09-23 Qanatpharma Ag Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
WO2020061103A1 (en) 2018-09-18 2020-03-26 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
US10675274B2 (en) 2018-09-19 2020-06-09 Forma Therapeutics, Inc. Activating pyruvate kinase R
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
AU2019366312B2 (en) 2018-10-22 2025-04-24 Novartis Ag Crystalline forms of potassium channel modulators
KR102880470B1 (ko) * 2018-10-23 2025-11-03 다이이찌 산쿄 가부시키가이샤 바이아릴 유도체
EP3877382B1 (en) 2018-11-07 2026-03-18 Tianli Biotech Pty Ltd Novel compounds for the treatment of respiratory diseases
CN109503563B (zh) * 2018-12-10 2020-05-12 济南大学 多功能乙酰胆碱酯酶抑制剂及其应用
KR102128509B1 (ko) 2018-12-19 2020-07-01 한국과학기술연구원 말단 아민기에 아릴 또는 헤테로아릴기가 치환된 신규한 히드라존 유도체 및 이의 용도
US20220073470A1 (en) * 2019-01-04 2022-03-10 Bellbrook Labs, Llc Inhibitors of cgas activity as therapeutic agents
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
US12098146B2 (en) 2019-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US12351577B2 (en) 2019-03-15 2025-07-08 Forma Therapeutics, Inc. Inhibiting cyclic AMP-responsive element-binding protein (CREB)
KR102939516B1 (ko) 2019-04-26 2026-03-16 셀진 코포레이션 헤테로시클릭 화합물 및 연충 감염 및 질환의 치료를 위한 그의 용도
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
PH12021553107A1 (en) 2019-06-18 2022-08-01 Ctxt Pty Ltd Benzisoxazole sulfonamide derivatives
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11535621B2 (en) 2019-07-31 2022-12-27 Ribon Therapeutics, Inc. Heterobicyclic amides as inhibitors of CD38
RU2746423C2 (ru) * 2019-09-02 2021-04-13 Общество с ограниченной ответственностью "Научно-исследовательский институт ХимРар" (ООО "НИИ ХимРар") Ингибитор вируса гепатита В (ВГВ)
HUE072832T2 (hu) 2019-09-19 2025-12-28 Novo Nordisk Healthcare Ag Piruvát kináz R-t (PKR) aktiváló készítmények
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
US12343335B2 (en) 2019-11-14 2025-07-01 Zincure Corp. Pharmaceutical composition for treating multiple sclerosis on basis of AMPK inhibitory function and zinc homeostasis control function
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
MX2022006865A (es) 2019-12-06 2022-07-11 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AR122711A1 (es) * 2020-06-25 2022-09-28 Alchemedicine Inc COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA
WO2022035805A1 (en) * 2020-08-10 2022-02-17 Dana-Farber Cancer Institute, Inc. Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
US20230339900A1 (en) * 2020-09-17 2023-10-26 Janssen Pharmaceutica Nv Casein kinase 1 delta modulators
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
GB202101734D0 (en) * 2021-02-08 2021-03-24 Cerevance Inc Novel Compounds
JP2024507253A (ja) 2021-02-19 2024-02-16 スドー バイオサイエンシーズ リミテッド Ｔｙｋ２阻害剤およびその使用
JP2024508794A (ja) 2021-02-19 2024-02-28 スドー バイオサイエンシーズ リミテッド Ｔｙｋ２阻害剤およびその使用
CA3207819A1 (en) 2021-02-19 2022-08-25 Anjali Pandey Tyk2 inhibitors and uses thereof
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
KR102910851B1 (ko) * 2021-04-21 2026-01-09 장춘 진사이언스 파마슈티컬 씨오., 엘티디. 이미다졸 함유 축합고리계 유도체, 이의 제조방법 및 이의 의약적 용도
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
EP4352060A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
CA3233233A1 (en) * 2021-10-15 2023-04-20 Ruben Abagyan Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof
JP2025513455A (ja) 2022-04-22 2025-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド 疼痛の治療のためのヘテロアリール化合物
CN115466211B (zh) * 2022-06-09 2024-02-23 中国人民解放军空军军医大学 一种n-苯基喹啉-4-胺类化合物及其应用
JP2025525514A (ja) * 2022-07-14 2025-08-05 シャンハイ、レイジング、ファーマシューティカル、カンパニー、リミテッド Ｔｐｋアゴニスト及びそれを用いた神経変性疾患の治療方法
US12600723B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
US12600722B2 (en) 2022-07-18 2026-04-14 Incyte Corporation Tetracyclic compounds as DGK inhibitors
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
EP4574826A4 (en) * 2022-10-19 2025-12-10 Changchun Genescience Pharmaceutical Co Ltd CRYSTALLINE FORM OF AN NK3R ANTAGONIST, ITS PREPARATION PROCESS AND ITS USE
CN120917015A (zh) * 2023-01-20 2025-11-07 元启(苏州)生物制药有限公司 Srpk1抑制剂和使用方法
EP4660182A1 (en) * 2023-01-30 2025-12-10 Eurofarma Laboratórios S.A. Nav1.7- and/or nav1.8-inhibiting aryl pyridine compounds, processes for the preparation thereof, compositions, uses, methods for treatment using same, and kits
PY2404641A (es) * 2023-01-30 2024-10-03 Eurofarma Laboratorios S A COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y SUS KITS
IT202400002560A1 (it) * 2024-02-07 2025-08-07 Univ Pisa Inibitori della proteina rock per uso nel trattamento della fibrosi polmonare
CN118666857B (zh) * 2024-06-26 2025-02-25 江西农业大学 一种喹啉类化合物及其在农用杀菌剂中的应用
CN119060061B (zh) * 2024-08-26 2025-09-16 浙江师范大学 一类苯并嘧啶硫醚类化合物作为sting蛋白小分子抑制剂的应用
WO2026062521A2 (en) 2024-09-18 2026-03-26 Institute Of Molecular And Clinical Ophthalmology Basel (Iob) Methods and compounds for promoting survival of photoreceptors

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5545656A (en) * 1995-04-05 1996-08-13 Pfizer Inc. 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease
US20030219427A1 (en) * 1998-08-18 2003-11-27 Allen Hamish J. TPL-2/COT kinase and methods of use
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6087363A (en) * 1999-07-16 2000-07-11 Harbor Branch Oceanographic Institution, Inc. Use of imidazole and indole compounds as inhibitors of nitric oxide synthase
AU1224902A (en) * 2000-09-01 2002-03-13 Sanofi Synthelabo 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2-a)pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo(1,2-a)pyrimidin-5(1H)one derivatives
ES2266258T3 (es) * 2000-09-15 2007-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de proteina cinasas.
JP2004524289A (ja) * 2000-12-22 2004-08-12 アストラゼネカ・アクチエボラーグ 治療化合物
ES2295441T3 (es) * 2001-12-18 2008-04-16 MERCK & CO., INC. Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato.
JP2003212859A (ja) * 2002-01-24 2003-07-30 Nippon Nohyaku Co Ltd 置換フェニルヘテロ環類及びこれを有効成分とする除草剤
CA2477984A1 (en) * 2002-03-08 2003-09-18 Pamela Ann Albaugh Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors
FR2836915B1 (fr) * 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
WO2003097615A1 (en) * 2002-05-17 2003-11-27 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
AU2003242233A1 (en) * 2002-06-12 2003-12-31 Bf Research Institute, Inc. Probe compound for image diagnosis of disease with amyloid accumulation, compound for staining age spots/diffuse age spots, and remedy for disease with amyloid accumulation
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
US7060698B2 (en) * 2003-05-19 2006-06-13 Hoffmann-La Roche Inc. Benzoxazepinone derivatives
EP1631145A4 (en) * 2003-06-06 2009-12-23 Univ Pennsylvania COMPOSITIONS COMPRISING P38 KINASE INHIBITORS AND METHODS OF USE
GB0314943D0 (en) 2003-06-25 2003-07-30 Proteome Sciences Plc Screening methods
DE602005024382D1 (de) * 2004-04-13 2010-12-09 Astellas Pharma Inc Polycyclische pyrimidine als kaliumionenkanal-modulatoren
AU2005277460A1 (en) * 2004-08-19 2006-03-02 Aventis Pharmaceuticals Inc. 3-arylthioindole-2-carboxamide derivatives and analogs thereof as inhibitors of casein kinase I epsilon
WO2007015866A2 (en) * 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
EP1842541A1 (en) * 2006-03-29 2007-10-10 G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg Plant components and extracts and uses thereof
TW200813035A (en) * 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
EP2034993A2 (en) * 2006-06-21 2009-03-18 E.I. Du Pont De Nemours And Company Pyrazinones as cellular proliferation inhibitors
US7622495B2 (en) * 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
AU2007316257A1 (en) * 2006-11-02 2008-05-08 F. Hoffmann-La Roche Ag Substituted 2-imidazoles as modulators of the trace amine associated receptors
EP2081892A4 (en) * 2006-11-17 2014-03-05 Donald F Weaver COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE
ES2446269T3 (es) * 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
CA2689575A1 (en) * 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Cetp inhibitors derived from benzoxazole arylamides
FR2918061B1 (fr) * 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
FR2918986B1 (fr) * 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
GB0715939D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
EP2220499A2 (en) * 2007-11-28 2010-08-25 Yale University Nogo receptor binding small molecules to promote axonal growth
US8642660B2 (en) * 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2149551A1 (de) * 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
FR2934994B1 (fr) * 2008-08-12 2010-09-17 Sanofi Aventis Derives de 2-alkyl-6cycloamino-3-(pyridin-4-yl)imidaz°1,2-b! pyridazine, leur preparation et leur application en therapeutique
KR101257695B1 (ko) * 2008-12-24 2013-04-24 제일모직주식회사 신규한 유기광전소자용 화합물 및 이를 포함하는 유기광전소자
FR2945289A1 (fr) * 2009-05-11 2010-11-12 Sanofi Aventis Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
CN102811620B (zh) * 2010-01-25 2015-03-25 Chdi基金会股份有限公司 一些犬尿氨酸-3-单加氧酶抑制剂、药物组合物及其使用方法
US20140031547A1 (en) * 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
CN103842362B (zh) 2011-05-09 2017-05-24 爱普制药有限责任公司 用于治疗阿尔茨海默氏病的组合物和方法

Similar Documents

Publication Publication Date Title
WO2012080729A4 (en) Casein kinase 1delta (ck1delta) inhibitors and their use in the treatment of neurodegenerative diseases such as tauopathies
JP2014503527A5 (enExample)
RU2423354C2 (ru) Соединения и композиции - модуляторы сигнального пути hedgehog
HRP20180916T1 (hr) Inhibitori demetilaze od lsd1 na bazi arilciklopropilamina i njihova medicinska uporaba
JP2022500472A5 (enExample)
JP2018522823A5 (enExample)
RU2012143897A (ru) Замещенные пиримидины как антагонисты рецепторов простагландина d2
JP2020519606A5 (enExample)
JP2016505614A5 (enExample)
JP2017533968A5 (enExample)
RU2017134866A (ru) Соединения бензазепина дикарбоксамида
RU2008110949A (ru) Соединения и композиции-иммуносупрессанты
JP2008513516A5 (enExample)
JP2013535460A5 (enExample)
JP2009534386A5 (enExample)
JP2017538785A5 (enExample)
JP2015516429A5 (enExample)
ME03723B (me) 2-amin0-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridini kао васе1 inhibiтori
JP2012532125A5 (enExample)
RU2015120556A (ru) Ингибиторы гликозидаз и их применения
JP2017504652A5 (enExample)
JP2019537592A5 (enExample)
JP2013542980A5 (enExample)
JP2011510985A5 (enExample)
JP2020500192A5 (enExample)